High-accuracy biodistribution analysis of adeno-associated virus variants by double barcode sequencing  Damien Marsic, Héctor R Méndez-Gómez, Sergei Zolotukhin 

Slides:



Advertisements
Similar presentations
Molecular Therapy - Methods & Clinical Development
Advertisements

Genetic Manipulation of Brown Fat Via Oral Administration of an Engineered Recombinant Adeno-associated Viral Serotype Vector  Wei Huang, Travis McMurphy,
Molecular Therapy - Methods & Clinical Development
Volume 15, Issue 6, Pages (June 2007)
Molecular Therapy - Methods & Clinical Development
Volume 23, Issue 1, Pages (January 2015)
Volume 16, Issue 3, Pages (March 2008)
Volume 8, Issue 2, Pages (August 2003)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Molecular Therapy - Methods & Clinical Development
Comparison of BIOMED-2 Versus Laboratory-Developed Polymerase Chain Reaction Assays for Detecting T-Cell Receptor-γ Gene Rearrangements  Keyur P. Patel,
A MicroRNA124 Target Sequence Restores Astrocyte Specificity of gfaABC1D-Driven Transgene Expression in AAV-Mediated Gene Transfer  Grit Taschenberger,
Molecular Therapy - Methods & Clinical Development
Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes  Yoshitaka Miyagawa,
Tissue-specific Calibration of Real-time PCR Facilitates Absolute Quantification of Plasmid DNA in Biodistribution Studies  Joan K Ho, Paul J White, Colin.
Molecular Therapy  Volume 20, Pages S261-S262 (May 2012) DOI: /S (16)
Volume 16, Issue 3, Pages (March 2008)
Molecular Therapy - Methods & Clinical Development
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Volume 4, Issue 6, Pages (December 2001)
Volume 2, Issue 5, Pages (November 2000)
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Volume 13, Issue 4, Pages (April 2006)
Vaccinia virus as a subhelper for AAV replication and packaging
Molecular Therapy - Methods & Clinical Development
Volume 23, Issue 12, Pages (December 2015)
Volume 25, Issue 12, Pages (December 2017)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Methods & Clinical Development
Helper virus-mediated downregulation of transgene expression permits production of recalcitrant helper-dependent adenoviral vector  Donna J Palmer, Nathan.
Volume 15, Issue 5, Pages (May 2007)
Volume 5, Issue 2, Pages (February 2002)
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Systemic Mannitol-Induced Hyperosmolality Amplifies rAAV2-Mediated Striatal Transduction to a Greater Extent Than Local Co-infusion  Corinna Burger, Frederic.
Targeting Dyrk1A with AAVshRNA Attenuates Motor Alterations in TgDyrk1A, a Mouse Model of Down Syndrome  Jon Ortiz-Abalia, Ignasi Sahún, Xavier Altafaj,
Volume 15, Issue 1, Pages (January 2007)
Volume 3, Issue 4, Pages (April 2001)
Volume 6, Issue 1, Pages (July 2002)
Volume 18, Issue 1, Pages (January 2010)
Volume 16, Issue 6, Pages (June 2008)
piggyBac Transposon-mediated Long-term Gene Expression in Mice
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Volume 19, Issue 4, Pages (April 2011)
Molecular Therapy - Nucleic Acids
Mathieu Nonnenmacher, Harm van Bakel, Roger J Hajjar, Thomas Weber 
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Volume 8, Issue 2, Pages (August 2003)
Volume 18, Issue 3, Pages (March 2010)
Rational Design of Therapeutic siRNAs: Minimizing Off-targeting Potential to Improve the Safety of RNAi Therapy for Huntington's Disease  Ryan L Boudreau,
Kasey L Jackson, Robert D Dayton, Ronald L Klein 
Volume 6, Issue 3, Pages (September 2002)
Volume 24, Issue 1, Pages (January 2016)
Single-Shot, Multicycle Suicide Gene Therapy by Replication-Competent Retrovirus Vectors Achieves Long-Term Survival Benefit in Experimental Glioma  Chien-Kuo.
Fetal Brain-directed AAV Gene Therapy Results in Rapid, Robust, and Persistent Transduction of Mouse Choroid Plexus Epithelia  Marie Reine Haddad, Anthony.
Molecular Therapy - Methods & Clinical Development
Thomas Gaj, Benjamin E Epstein, David V Schaffer  Molecular Therapy 
Evidence for Encapsidation of Prokaryotic Sequences during Recombinant Adeno- Associated Virus Production and Their in Vivo Persistence after Vector Delivery 
Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes  Yoshitaka Miyagawa,
Volume 8, Issue 1, Pages (July 2003)
Molecular Therapy - Methods & Clinical Development
Volume 13, Issue 1, Pages (January 2006)
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Presentation transcript:

High-accuracy biodistribution analysis of adeno-associated virus variants by double barcode sequencing  Damien Marsic, Héctor R Méndez-Gómez, Sergei Zolotukhin  Molecular Therapy - Methods & Clinical Development  Volume 2, (January 2015) DOI: 10.1038/mtm.2015.41 Copyright © 2015 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Overview of the experiment. Diagram of barcoded AAV transgene cassette (a). CBA promoter, CMV-b-actin promoter; 2A peptide, foot-and-mouth disease virus 2A ribosomal skip peptide; Barcode: 6-nt unique sequence identifier; ITR, AAV2 terminal repeat; PolyA, bovine growth hormone gene polyadenylation site. Note that elements are not drawn to scale. Global flowchart (b). The barcoded AAV mixture (top left) is injected into animals; tissue samples are harvested (bottom left); DNA is isolated from all samples; DNA is quantified and used as a template in quantitative polymerase chain reaction (qPCR) to titer total AAV in each sample (bottom right); DNA is also used as PCR template, as well as the original AAV mixture, to amplify AAV-specific barcodes using sample-specific barcoded primers; all PCR products are then combined and sequenced in a single reaction to determine the variant composition in each sample; sequencing data are then used, in conjunction with viral titers to compute biodistribution for each variant (top right). Molecular Therapy - Methods & Clinical Development 2015 2, DOI: (10.1038/mtm.2015.41) Copyright © 2015 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Evaluation of luciferase and mApple signals in the mouse model. Intense BLI signal was detected in the right leg of the mouse 2 weeks after intramuscular injection of AAV5-luciferase-mApple (c). BLI signal located in the skull was detected in a mouse that received a stereotactic injection of AAV5-luciferase-mApple in the right striatum (d). Note the absence of BLI signal before the intraperitoneal injection of luciferin (a,b). The pseudo-color scale represents the intensity of light emitted in number of counts. Max and Min are the maximum and the minimum number of counts respectively. Further analysis of a coronal section of the brain confirms that the BLI signal comes from the right striatum (e). Fluorescent signal examination reveals that mApple signal is located in the same anatomic location as luciferase (f). Fluorescent immunohistochemistry of luciferase and subsequent confocal analysis validates colocalization of luciferase (g) and mApple (h) at the cellular level. Image i is a merge of g and h. Scale bars: 1.8 mm (e,f), 11.7 µm (g–i), 6 µm (g–i magnifications). Molecular Therapy - Methods & Clinical Development 2015 2, DOI: (10.1038/mtm.2015.41) Copyright © 2015 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Global biodistribution. Distribution of unspecified viral genomes in tissue samples from three animals, derived from quantitative polymerase chain reaction titers. Molecular Therapy - Methods & Clinical Development 2015 2, DOI: (10.1038/mtm.2015.41) Copyright © 2015 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Comprehensive biodistribution. Distribution of viral genomes in tissue samples derived from global biodistribution combined with barcode sequencing (mean values from three animals). AAV, adeno-associated virus. Molecular Therapy - Methods & Clinical Development 2015 2, DOI: (10.1038/mtm.2015.41) Copyright © 2015 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 Effects of PCR cycles on variant composition. PCR, polymerase chain reaction. Molecular Therapy - Methods & Clinical Development 2015 2, DOI: (10.1038/mtm.2015.41) Copyright © 2015 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions